| Yvonne C Smela, RPH | |
|
2500 S Havana St, Aurora, CO 80014-1618 | |
| (303) 338-4434 | |
| Not Available |
| Full Name | Yvonne C Smela |
|---|---|
| Gender | Female |
| Speciality | General Practice |
| Location | 2500 S Havana St, Aurora, Colorado |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1871637652 | NPI | - | NPPES |
| 003864 | Other | KAISER-COMMERCIAL NUMBER |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208D00000X | General Practice | 14146 (Colorado) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Yvonne C Smela, RPH 2500 S Havana St, Aurora, CO 80014 Ph: (303) 338-4434 | Yvonne C Smela, RPH 2500 S Havana St, Aurora, CO 80014-1618 Ph: (303) 338-4434 |
News Archive
...according to an analysis of previously published research in the April 9 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.
Achillion Pharmaceuticals, Inc., a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that it has entered into definitive agreements for the purchase of $50.1 million of Achillion's common stock and warrants in a private placement financing with a select group of institutional and accredited investors, namely Domain Associates, Clarus Ventures, Quaker BioVentures and Pappas Ventures.
Howard Kornblum has been watching every penny for the past 15 months and it's about to get worse. After being laid off from his job as a consulting director in Michigan, he took advantage in March 2009 of a federal subsidy to help pay for health insurance.
Oramed Pharmaceuticals Inc., a developer of oral drug delivery systems, announced today that it has filed a provisional patent application with the United States Patent and Trademark Office for a combination therapy of its lead compound, ORMD-0801 in combination with its oral exenatide formulation, ORMD-0901. There is no such approved combination product available on the market today.
Aeterna Zentaris Inc. today announced that the Phase 3 "X-PECT" (Xeloda + Perifosine Evaluation in Colorectal cancer Treatment) clinical trial evaluating perifosine + capecitabine (Xeloda) in patients with refractory advanced colorectal cancer did not meet the primary endpoint of improving overall survival versus capecitabine + placebo.
› Verified 4 days ago
Judy W Christensen, General Practice Medicare: Not Enrolled in Medicare Practice Location: 2500 S Havana St, Aurora, CO 80014 Phone: 303-338-4434 | |
Edward D Bordas Jr, General Practice Medicare: Not Enrolled in Medicare Practice Location: 2500 S Havana St, Aurora, CO 80014 Phone: 303-338-4503 | |
Bola R Yafet, General Practice Medicare: Not Enrolled in Medicare Practice Location: 16601 E Centretech Pkwy, Aurora, CO 80011 Phone: 720-536-7933 | |
Dr. Jiaochen Ke, MD General Practice Medicare: Medicare Enrolled Practice Location: 1890 N Revere Ct Ste 4100, Aurora, CO 80045 Phone: 303-724-6021 | |
Sally J Sjobeck, General Practice Medicare: Not Enrolled in Medicare Practice Location: 2500 S Havana St, Aurora, CO 80014 Phone: 303-283-2813 | |
Beverly J Kruse, General Practice Medicare: Not Enrolled in Medicare Practice Location: 2500 S Havana St, Aurora, CO 80014 Phone: 303-338-3800 | |
Shakti Bachmann, PHARM.D. General Practice Medicare: Not Enrolled in Medicare Practice Location: 2500 S Havana St, Aurora, CO 80014 Phone: 303-743-5855 |